Commercial Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval Pharmaceutical TechnologyIonis has forecast peak sales of $2bn for Tryngolza as it seeks to harness first-mover advantage.CardiovascularRead full story pharminent June 26, 2026 (Last updated: July 1, 2026) Pharmaceutical Technology Ionis has forecast peak sales of $2bn for Tryngolza as it seeks to harness first-mover advantage. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Ionis grants Recordati rights to zilganersen for Alexander diseaseNext: Immunai and Boehringer partner to identify T-cell targets Related Stories Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026 Commercial Lilly launches its LillyDirect sales channel in the UK pharminent June 25, 2026 Commercial Post-marketing oncology studies: Enabling faster recruitment and lower costs pharminent June 22, 2026
